Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study

Blood

Volumn 122, Issue 4, 2013, Pages 515-522

  Ross, David M ^a,d   Branford, Susan ^a   Seymour, John F ^b,e   Schwarer, Anthony P ^b,f   Arthur, Christopher ^b,g   Yeung, David T ^a,c   Dang, Phuong ^a   Goyne, Jarrad M ^a   Slader, Cassandra ^h   Filshie, Robin J ^b,i   Mills, Anthony K ^b,j   Melo, Junia V ^a,c   White, Deborah L ^a,c   Grigg, Andrew P ^b,k   Hughes, Timothy P ^a,c  

^a SA Pathology   (Australia)

^b Australasian Leukaemia Lymphoma Group   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d FLINDERS UNIVERSITY   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g ROYAL NORTH SHORE HOSPITAL   (Australia)

^h Novartis Pharmaceuticals   (Australia)

ⁱ ST VINCENT S HOSPITAL   (Australia)

^j PRINCESS ALEXANDRA HOSPITAL   (Australia)

^k ROYAL MELBOURNE HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DNA; IMATINIB; INTERFERON; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKEMIA RELAPSE; MALE; MINIMAL RESIDUAL DISEASE; PATIENT SAFETY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RISK; TREATMENT DURATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PIPERAZINES; PYRIMIDINES; RECURRENCE; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84886917643     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-483750     Document Type: Article

References (37)

1. Hughes TP, Kaeda J, Branford S., et al.; International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349(15): 1423-1432. (Pubitemid 37211057)
2. Hughes T, Deininger M, Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108(1): 28-37. (Pubitemid 43990609)
3. Branford S, Seymour JF, Grigg A, Arthur C., Rudzki Z, Lynch K, Hughes T. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007; 13(23): 7080-7085. (Pubitemid 350276891)
4. Baccarani M, Cortes J, Pane F., et al.; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35): 6041-6051.
5. Rousselot P, Huguet F, Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007; 109(1): 58-60. (Pubitemid 46053043)
6. Mahon FX, Réa D, Guilhot J., et al.; Intergroupe Français des Leucé mies Myélöides Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010; 11(11): 1029-1035.
7. Takahashi N, Kyo T, Maeda Y., et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012; 97(6): 903-906.
8. Verma D, Kantarjian H, Jain N., Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma. 2008; 49(7): 1399-1402. (Pubitemid 352015805)
9. Rea D, Rousselot P, Nicolini F., et al. Cessation of dasatinib or nilotinib therapy in chronic-phase chronic myeloid leukaemia patients with sustained complete molecular responses [abstract]. Haematologica. 2011; 96(S2). Abstract 1014.
10. Ross DM, Bartley PA, Goyne J, Morley A.A., Seymour JF, Grigg AP. Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features. Haematologica. 2011; 96(11): 1720-1722.
11. Yhim HY, Lee NR, Song E.K., et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res. 2012; 36(6): 689-693.
12. Rea D, Rousselot P, Guilhot F., et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts [abstract]. Blood. 2012; 120(21). Abstract 916.
13. Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol Med. 2006; 125: 69-92.
14. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003; 17(12): 2318-2357. (Pubitemid 38072573)
15. Ross DM, Branford S, Seymour J.F., et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia. 2010; 24(10): 1719-1724.
16. Hughes TP, Grigg A, Szer J., et al. Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control. Br J Haematol. 1997; 96(3): 635-640. (Pubitemid 27087254)
17. Branford S, Yeung DT, Prime J.A., et al. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood. 2012; 119(18): 4264-4271.
18. Branford S, Yeung DT, Ross D.M., et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013; 121(19): 3818-3824.
19. Cross NC, White HE, Müller MC, Saglio G., Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012; 26(10): 2172-2175.
20. Sobrinho-Simões M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood. 2010; 116(8): 1329-1335.
21. Goh HG, Lin M, Fukushima T., et al. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. Leuk Lymphoma. 2011; 52(5): 896-904.
22. Michor F, Hughes TP, Iwasa Y, Branford S., Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 2005; 435(7046): 1267-1270. (Pubitemid 40943094)
23. Roeder I, Horn M, Glauche I., Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications. Nat Med. 2006; 12(10): 1181-1184. (Pubitemid 44527354)
24. Krönke J., Schlenk RF, Jensen K.O., et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011; 29(19): 2709-2716.
25. Grimwade D, Jovanovic JV, Hills R.K., et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009; 27(22): 3650-3658.
26. Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002; 20(1): 214-220. (Pubitemid 34032614)
27. Kaeda J, O'Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy. Blood. 2006; 107(10): 4171-4176. (Pubitemid 43726829)
28. Lange T, Bumm T, Mueller M., et al. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. Leukemia. 2005; 19(7): 1262-1265. (Pubitemid 40946013)
29. Radich JP, Gehly G, Gooley T., et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995; 85(9): 2632-2638.
30. Goldman J, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006; 47(1): 1-7. (Pubitemid 43101717)
31. Burchert A, Müller MC, Kostrewa P., et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol. 2010; 28(8): 1429-1435.
32. Burchert A, Wölfl S, Schmidt M., et al. Interferonalpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood. 2003; 101(1): 259-264. (Pubitemid 36025916)
33. Molldrem JJ, Lee PP, Wang C, Felio K., Kantarjian HM, Champlin RE, Davis MM. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000; 6(9): 1018-1023.
34. Melo JV, Ross DM. Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematology Am Soc Hematol Educ Program. 2011; 136-142.
35. Lenaerts T, Pacheco JM, Traulsen A, Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica. 2010; 95(6): 900-907.
36. Haferlach T, Winkemann M, Nickenig C., et al. Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol. 1997; 97(1): 99-106. (Pubitemid 27179569)
37. Tang M, Foo J, Gönen M, Guilhot J., Mahon FX, Michor F. Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials. Haematologica. 2012; 97(10): 1553-1561.